

ACKNOWLEDGEMENTS

International Conference on Malignant Lymphoma (ICML) President

F. Cavalli, Bellinzona (Switzerland)

Chairman of ICML Organizing Committee

M. Ghilmini, Bellinzona (Switzerland)

Organizing Committee

J.O. Armitage, Omaha, NE (USA)

F. Bertoni, Bellinzona (Switzerland)

M.F. Fey, Bern (Switzerland)

R. Gascoyne, Vancouver, BC (Canada)

M.K. Gospodarowicz, Toronto, ON (Canada)

P.W.M. Johnson, Southampton (UK)

T. A. Lister, London (UK)

E. Zucca, Bellinzona (Switzerland)

Advisory Board

E. Campo, Barcelona (Spain)

B.D. Cheson, Washington, DC (USA)

J.M. Connors, Vancouver, BC (Canada)

F.E. Cotter, London (UK)

R. Dalla-Favera, New York, NY (USA)

M. Dreyling, Munich (Germany)

A. Engert, Cologne (Germany)

J.W. Friedberg, Rochester, NY (USA)

G. Gaidano, Novara (Italy)

P. Gaulard, Créteil (France)

M. Hallek, Cologne (Germany)

N.L. Harris, Boston, MA (USA)

E.S. Jaffe, Bethesda, MD (USA)

J.P. Leonard, New York, NY (USA)

A. Lopez-Guillermo, Barcelona (Spain)

M.A. Piris, Santander (Spain)

S.A. Pileri, Bologna (Italy)

S.V. Rajkumar, Rochester, MN (USA)

A. Reiter, Giessen (Germany)

F. Sallusto, Bellinzona (Switzerland)

M. Seto, Nagoya (Japan)

J.F. Seymour, Melbourne (Australia)

M.A. Shipp, Boston, MA (USA)

L. Specht, Copenhagen (Denmark)

L.M. Staudt, Bethesda, MD (USA)

C. Thieblemont, Paris (France)

K. Tobinai, Tokyo (Japan)

U. Vitolo, Turin (Italy)

D.D. Weisenburger, Duarte, CA (USA)

A. Younes, New York, NY (USA)

Conference Secretariat and Local Organization

C. Brentan, O. Lugli, C. Saporiti

Bellinzona (Switzerland)

The conference organizers wish to thank the following sponsors for their unrestricted financial support:

Affymetrix UK Ltd.

Baxter

Bristol Myers Squibb SA

CALYM, the Carnot Lymphoma Institute

Celgene Corporation

CTI Life Sciences

Cytocell Ltd

F. Hoffmann-La Roche Limited

Gilead Sciences, Inc.

GlaxoSmithKline Oncology

Helsinn Healthcare SA

Janssen Pharmaceuticals

Lilly Oncology

Lipomed AG

Millennium: The Takeda Oncology Company

Mundipharma International Ltd

Mundipharma Medical Company

Novartis Pharmaceuticals Corporation

OrPha Swiss

Pfizer Oncology

Pharmacyclics Inc.

prIME Oncology

Ruwag Handels AG

Seattle Genetics

sigma-tau Research Switzerland SA

Spectrum Pharmaceuticals, Inc.

Terumo BCT

Varian Medical Systems

The conference organizers wish to thank the following contributors for their support:

American Society of Clinical Oncology (ASCO)

Banca dello Stato del Canton Ticino

BSI SA

City of Lugano

Comunità Tariffale Ticino e Moesano

Electronic Studio SA

European School of Oncology (ESO)

European School of Oncology Foundation (ESOF)

European Society for Medical Oncology (ESMO)

European Society for Radiotherapy and Oncology (ESTRO)

GSI Suisse

Hotel Splendide Royal

International Lymphoma Radiation Oncology Group (ILROG)

Repubblica e Cantone Ticino – Fondo Swisslos

Swiss Academy of Medical Sciences (SAMS)

Swiss Cancer League

Swiss International Air Lines Ltd

SATELLITE SYMPOSIA SCHEDULE Tuesday, June 18, 2013**Tuesday, June 18, 2013**

| | |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:00–15:00 | Pharmacyclics, Inc./Janssen Pharmaceuticals, Inc. ADVANCEMENTS IN THE TREATMENT OF B-CELL MALIGNANCIES (Room BII) Chair: B.D. Cheson, Washington DC (USA) |
| 16:00–18:00 (Two parallel symposia) | Gilead Sciences, Inc. (supported by an unrestricted educational grant from) PI3 KINASE δ INHIBITORS AND THEIR ROLE IN LYMPHOID MALIGNANCIES (Room BI) Chair: F. Cavalli, Bellinzona (Switzerland) |
| | Pfizer Oncology TREATING AGGRESSIVE LYMPHOMAS: BETWEEN GUIDELINES, CLINICAL TRIALS AND REAL LIFE (Room BII) Chair: M. Ghielmini, Bellinzona (Switzerland) |
| 19:00–21:00 (Two Parallel symposia) | F. Hoffmann-La Roche Limited INNOVATIONS IN ANTIBODY THERAPY FOR LYMPHOID MALIGNANCY (Room A) Chair: F. Cavalli, Bellinzona (Switzerland) |
| | CTI Life Sciences (symposium organized and funded by) CURRENT PERSPECTIVE ON THE TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE B-CELL NHL (Room BI) Chair: M. Ghielmini, Bellinzona (Switzerland) |
| | prIME Oncology (supported by an unrestricted educational grant from Takeda & Millennium: The Takeda Oncology Company) NEW OPPORTUNITIES AND NEW CHALLENGES IN IMPROVING OUTCOMES FOR PATIENTS WITH CD30+ HEMATOLOGIC MALIGNANCIES (Room BII) Chair: T. Illidge, Manchester (UK) |

Wednesday, June 19, 2013

| | |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 19:00–21:00 (Two parallel symposia) | Mundipharma International Ltd MAKING SENSE OF THE RAPIDLY CHANGING WORLD OF LYMPHOMA (Room A) Chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Czuczman, Buffalo, NY (USA) |
| | Celgene Corporation FROM BENCH TO BEDSIDE—TRANSLATING PRECLINICAL RESEARCH INTO CLINICAL REALITY (Room B) Chair: B.D. Cheson, Washington DC (USA) |

Thursday, June 20, 2013

| | |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 19:00–21:00 (Two parallel symposia) | prIME Oncology OPTIMIZING OUTCOMES FOR INDOLENT NON-HODGKIN LYMPHOMA AND MANTLE CELL LYMPHOMA (Room A) Chair: J.O. Armitage, Omaha, NE (USA) |
| | Mundipharma International Ltd CAN WE ERADICATE THE CNS DISEASE IN LYMPHOMA? (Room B) Chairs: C. Gisselbrecht, Paris (France) and E. Thiel, Berlin (Germany) |

Friday, June 21, 2013

18:45 – 19:45

IOSI – ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND

(supported by an unrestricted educational grant from MUNDIPHARMA INTERNATIONAL LTD.)

PROS AND CONS OF FRONT LINE R-CHOP PLUS MAINTENANCE IN FL

(room B)

Chair: M. Ghilmini, Bellinzona (Switzerland)

CONFERENCE SCHEDULE

Tuesday, June 18, 2013

10:00–17:30

ESO WORKSHOP: “MOLECULAR HETEROGENEITY AND TAILORED TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA” ***(BY INVITATION ONLY**—USI Auditorium, University Campus Lugano)

Steering committee: F. Bertoni, Bellinzona (Switzerland), F.E. Cotter, London (UK); M.A. Shipp, Boston MA (USA); and E. Zucca, Bellinzona (Switzerland)

*Organized in co-operation with the European School of Oncology (ESO)




15:30–18:00

WORKSHOP: “MODERN RADIOTHERAPY FOR LYMPHOMAS—CONCEPTS AND TREATMENT GUIDELINES” ***(open to all I2-ICML attendees**—Room C)

Chair: L. Specht, Copenhagen (Denmark)

*Organized by International Lymphoma Radiation Oncology Group (ILROG)

Wednesday, June 19, 2013

| | |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8:30–12:00 | POSTER SET UP (Marquee Parco Ciani) |
| 9:00–10:30 (Two parallel sessions) | EDUCATIONAL SYMPOSIA  DIFFUSE LARGE B-CELL LYMPHOMA SUBTYPES (Room A) Chair: P.W.M. Johnson, Southampton (UK) <u>Lectures</u> I. Pathological and clinical diversity in DLBCL M.A. Piris, Santander (Spain) II. Therapy of DLBCL based on genomics L.M. Staudt, Bethesda, MD (USA) III. Applying molecular phenotyping in practice P.W.M. Johnson, Southampton (UK) MULTIPLE MYELOMA (Room B and Marquee Parco Ciani) Chair: S.V. Rajkumar, Rochester MN (USA) <u>Lectures</u> IV. Initial therapy of myeloma S.V. Rajkumar, Rochester, MN (USA) V. Molecular classification and risk stratification of myeloma P.L. Bergsagel, Scottsdale, AZ (USA) VI. Autologous stem cell transplantation and maintenance therapy P. Moreau, Nantes (France) |
| 9:00–9:45 (Three parallel sessions) | MEET THE PROFESSOR  VII. Management of nodular lymphocyte predominant Hodgkin's lymphoma (Cinema Corso) A. Engert, Cologne (Germany) VIII. New markers in T-cell lymphoma: more entities or more confusion? (USI Auditorium, University Campus Lugano) P. Gaulard, Créteil (France) IX. CLL: new genetic markers as prognostic factors (USI Aula Magna, University Campus Lugano) D. Rossi, Novara (Italy) |
| 10:00–10:45 (Three parallel sessions) | MEET THE PROFESSOR  X. Extranodal lymphomas in rare localisations (bone, breast and others) (Cinema Corso) J.F. Seymour, Melbourne (Australia) XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma? (USI Auditorium, University Campus Lugano) W. Woessmann, Giessen (Germany) XII. Hodgkin's lymphoma in the elderly (USI Aula Magna, University Campus Lugano) A.M. Evens, Worcester, MA (USA) |
| 10:45–11:10 | COFFEE BREAK (Marquee Parco Ciani) |
| 11:10–12:00 | CONTROVERSY I (Rooms A, B, and Marquee) Is R-CHOP the standard treatment for high risk DLBCL? Chair: U. Jäger, Wien (Austria) 004 Yes—J. Friedberg, Rochester, NY (USA) vs 005 No—F. Morschhauser, Lille (France) |
| 12:00–18:00 | POSTER SESSION * (Marquee Parco Ciani) *Printing of the posters sponsored by Mundipharma International Limited 161–171 Molecular biology 172–185 Clinicopathologic correlations 186–204 Indolent entities 205–226 Aggressive B-cell lymphoma 227–231 Mantle cell lymphoma |

(Continues)

(Continued)

Wednesday, June 19, 2013

| | | |
|-------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 232–238 | T-cell lymphomas |
| | 239–251 | Extranodal lymphomas |
| | 252–256 | Hodgkin's lymphoma |
| | 257–263 | CLL |
| | 264–269 | Transplantation |
| | 270–276 | Imaging |
| | 277–285 | New drugs pre-clinical |
| | 286–304 | New drugs clinical |
| | 305–310 | Paediatric lymphoma |
| 12:00–13:00 | | LUNCHTIME AND POSTER VIEWING (Marquee Parco Ciani) |
| 13:00–13:55 | | OPENING OF THE CONFERENCE (Rooms A, B, and Marquee Parco Ciani)  Welcome and introductory remarks F. Cavalli, Bellinzona (Switzerland) |
| 13:10 | | HENRY KAPLAN MEMORIAL LECTURE Supported by a special grant of the European School of Oncology Foundation – ESOF Introduction to ESOF: C. Maggini, Bellinzona (Switzerland) Laudatio: J.O. Armitage, Omaha, NE (USA) |
| | 001 | The evolution of lymphoma understanding and treatment from I-ICML (1981) To I2-ICML (2013) F. Cavalli, Bellinzona (Switzerland) |
| 14:00–15:00 | | PLENARY SESSION (Rooms A, B, and Marquee Parco Ciani) Chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli, Bellinzona (Switzerland) |
| 14:00 | 006 | Iterative germinal center re-entries of memory B-cells with T(14;18) translocation and early steps of follicular lymphoma progression S. Roulland, Marseille (France) Discussant: R. Gascoyne, Vancouver, BC (Canada) |
| 14:20 | 007 | Chlorambucil plus rituximab produces better event-free and progression-free survival in comparison with chlorambucil or rituximab alone in extranodal marginal zone B-cell lymphoma (malt lymphoma): final results of the IELSG-19 study E. Zucca, Bellinzona (Switzerland) Discussant: G. Nowakowski, Rochester MN (USA) |
| 14:40 | 008 | Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia (CLL) patients with 17p deletion A. Wiestner, Bethesda MD (USA) Discussant: S. Stilgenbauer, Ulm (Germany) |
| 15:00–15:30 | | COFFEE BREAK (Marquee Parco Ciani) |
| 15:30–17:00 | | SESSION I—BIOLOGY OF DIFFUSE LARGE B-CELL LYMPHOMA (Rooms A, B, and Marquee Parco Ciani) Chairs: F.E. Cotter, London (UK) and M.A. Shipp, Boston MA (USA) |
| 15:30 | 009 | Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma is a neoplasm with preferential activated gene expression signature whose outcome relies on CD30 expression: a report from the International DLBCL Rituximab-CHOP Consortium Program Study K.H. Young, Houston, TX (USA) |
| 15:45 | 010 | Therapeutic targeting of cell cycle deregulation in diffuse large B-cell lymphoma B. Chapuy, Boston MA (USA) |
| 16:00 | 011 | Integrated analysis identified deletion of CDKN2A as the most frequent and unique genomic abnormality in diffuse large B-cell lymphoma (DLBCL) with strong prognostic value not overcome by a dose-intensive immunochemotherapy. a LYSA study F. Jardin, Rouen (France) |

(Continues)

(Continued)

Wednesday, June 19, 2013

| | | |
|----------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16:15 | 012 | Biologic characterization of adult MYC-positive mature B-cell lymphomas other than molecular Burkitt lymphoma within the MMML cohort S.M. Aukema, Kiel (Germany) |
| 16:30 | 013 | Integrated sequence analyses of Burkitt, follicular and diffuse large B-cell lymphomas in the framework of the German ICGC MMML-Seq R. Siebert, Kiel (Germany) |
| 16:45 | | REPORT OF ESO WORKSHOP on "Molecular heterogeneity and tailored treatment of diffuse large B-cell lymphoma" M.A. Shipp, Boston MA (USA) |
| 17:15–18:15 (Six parallel sessions) | | 'FOCUS ON...' SESSIONS PET-GUIDED TREATMENT DECISIONS (Room A) Chair: T.A. Lister, London (UK) |
| 17:15 | 014 | Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma (DLBCL)? N.G. Mikhaeel, London (UK) |
| 17:25 | 015 | Final results of a prospective evaluation of the predictive value of interim pet in patients with DLBCL under R-CHOP-14 (SAKK 38/07) C. Mamot, Aarau (Switzerland) |
| 17:35 | 016 | Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404 L.J. Swinnen, Baltimore, MD (USA) |
| 17:45 | 017 | Evaluation of dual tracer (FLT and FDG) PET imaging as part of risk-adapted therapy for patients (PTS) with advanced stage diffuse large B cell lymphoma (DLBCL) C.H. Moskowitz, New York, NY (USA) |
| 17:55 | 018 | PET-CT for staging and early response—results from the response adapted therapy in advanced Hodgkin lymphoma (RATHL) study S.F. Barrington, London (UK) |
| 18:05 | 019 | Interim results of IIL-HD0801 study on early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkin's lymphoma patients with positive positron emission tomography after two courses of chemotherapy P.L. Zinzani, Bologna (Italy) |
| 17:15–18:15 | | TRANSPLANT STRATEGIES (Room B) Chair: S. Le Gouill, Nantes (France) |
| 17:15 | 020 | Bendamustin as part of conditioning regimen for autologous stem cell transplantation (ASCT) in patients with aggressive lymphomas: a Phase 2 study from Spanish Geltamo Group A. Martin, Salamanca (Spain) |
| 17:25 | 021 | High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B-cell lymphoma: a retrospective analysis from the adult lymphoma working group of the Japan Society for Hematopoietic cell transplantation D. Chihara, Nagoya (Japan) |
| 17:35 | 022 | Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation (ASCT) are similar to younger patients: a subgroup analysis from the Phase III NCIC CTG LY12 trial K. Davison, Toronto, Ontario (Canada) |
| 17:45 | 023 | Cord blood transplantation for adult T-cell leukemia/lymphoma (ATL): a retrospective analysis from the ATL working group of the Japan Society for Hematopoietic Cell Transplantation K. Kato, Fukuoka (Japan) |
| 17:55 | 024 | Outcomes of allogeneic stem cell transplantation for non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations: a single centre retrospective analysis M. Greenwood, Sydney (Australia) |

(Continues)

(Continued)

Wednesday, June 19, 2013

- | | | |
|-------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 18:05 | 025 | Long term outcomes after fluda/cyclophosphamide reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for lymphomas: a BHS national prospective trial D. Bron, Antwerpen (Belgium) |
| 17:15–18:15 | | PRECLINICAL ASSAYS (Room C) Chair: G. Gaidano, Novara (Italy) |
| 17:15 | 026 | Biomimetic synthetic high density lipoprotein nanostructures target the SR-BI receptor; differentially manipulate cellular cholesterol flux in lymphoma cells, and modify cell cycle, oxidation and cholesterol synthesis genes L.I. Gordon, Chicago, IL (USA) |
| 17:25 | 027 | Cross-species dissection of function, mechanism and predictive impact of therapy-related paracrine senescence in aggressive B-cell lymphoma in mice and men C.A. Schmitt, Berlin (Germany) |
| 17:35 | 028 | The novel proteasome inhibitor LU-102, but not bortezomib or carfilzomib, decreases p-IkB levels in myeloma cells, and is synergistic with ibrutinib to overcome bortezomib/carfilzomib resistance in vitro J. Kraus, St. Gallen (Switzerland) |
| 17:45 | 029 | Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor; ACY-1215 (ACY), and bortezomib (BOR), demonstrates synergistic antitumor activity in preclinical models of lymphoma J.E. Amengual, New York, NY (USA) |
| 17:55 | 030 | The novel 2nd generation proteasome inhibitor MLN9708 induces redox- and MAPK-related cell death in T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) cell lines and human lymphoma xenograft models A.M. Evens, Worcester, MA (USA) |
| 18:05 | 031 | Pharmacologic inhibition of MALT1 by distinct phenothiazines for a target-directed therapy of ABC-DLBCL D. Nagel, Neuherberg (Germany) |
| 17:15–18:15 | | EARLY AND LATE TOXICITIES (Cinema Corso) Chair: A. Moccia, Bellinzona (Switzerland) |
| 17:15 | 032 | Immunochemotherapy with bendamustine-rituximab (B-R) as induction therapy for indolent lymphomas results in a severe lymphopenia with low CD4+ and CD8+ counts without an increase in atypical infections. first results of the infectious disease (ID) project of a prospective, randomized, multicenter study (STIL NHL 7-2008-MAINTAIN-; NCT00877214) A. Burchardt, Giessen (Germany) |
| 17:25 | 033 | Risk of diabetes mellitus following treatment of Hodgkin lymphoma B.M. Aleman, Amsterdam (Netherlands) |
| 17:35 | 034 | Doses to carotid arteries after modern radiotherapy for Hodgkin lymphoma: is stroke still a late effect of treatment? M.V. Maraldo, Copenhagen (Denmark) |
| 17:45 | 035 | Risk factors for valvular heart disease following Hodgkin lymphoma D.J. Cutter, Oxford (UK) |
| 17:55 | 036 | Increased stomach cancer risk after treatment for Hodgkin lymphoma F. van Leeuwen, Amsterdam (Netherlands) |
| 18:05 | 037 | Second primary malignancies (SPM) in chronic lymphocytic leukemia (CLL)—a metaanalysis of four prospective trials of the German CLL study group P. Langerbeins, Cologne (Germany) |
| 17:15–18:05 | | NOVEL MONOCLONAL ANTIBODIES (USI Auditorium, University Campus Lugano) Chair: M. Czuczman, Buffalo, NY (USA) |
| 17:15 | 038 | Novel PI3K- δ inhibitors demonstrated marked cytotoxicity in T cell lymphoma models and were synergistic with a novel anti-CD20 mAb, ublituximab, in lymphoma models C. Deng, New York NY (USA) |

(Continues)

(Continued)

Wednesday, June 19, 2013

| | | |
|-------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:25 | 039 | Phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (PTS) with relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL) R. Advani, Stanford, CA (USA) |
| 17:35 | 040 | Phase I study of the anti-CD79B antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL) M.C. Palanca-Wessels, Seattle, WA (USA) |
| 17:45 | 041 | The efficacy and safety of mogamulizumab(KW-0761) in multicenter Phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma R. Ueda, Nagakute (Japan) |
| 17:55 | 042 | A Phase I study of bispecific CD30/CD16A TandAb antibody AFM13 in patients with relapsed or refractory Hodgkin lymphoma A. Engert, Cologne (Germany) |
| 17:15–18:15 | | LYMPHOMA AND THE CNS (USI Aula Magna, University Campus Lugano) Chair: A. Ferreri, Milan (Italy) |
| 17:15 | 043 | Development of novel patient-derived xenografts to dissect the pathogenesis of CNS lymphoma J. Rubenstein, San Francisco, CA (USA) |
| 17:25 | 044 | High efficiency of ice (ifosfamide-carboplatin-etoposide) in relapse/refractory primary central nervous system and intra-ocular non Hodgkin lymphoma, after first line treatment containing high doses of methotrexate (MTX) and cytarabine (ARAC). A multicentric retrospective study from 2010 to 2012 on 34 cases. A LOC network study S. Choquet, Paris (France) |
| 17:35 | 045 | Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary CNS lymphoma (PCNSL) in the elderly: a LOC national network study (INCA) C. Houillier, Paris (France) |
| 17:45 | 046 | Phase II trial of temsirolimus for relapsed/refractory primary central nervous system lymphoma (PCNSL) P. Kiewe, Berlin (Germany) |
| 17:55 | 047 | A new prognostic model to assess the risk of CNS disease in patients with aggressive B cell lymphoma N. Schmitz, Hamburg (Germany) |
| 18:05 | 048 | Extralympatic craniofacial diffuse large B-cell lymphoma: role of radiotherapy and intrathecal CNS prophylaxis N. Murawski, Homburg (Germany) |

Thursday, June 20, 20138:30–18:30 **POSTER SESSION** (Marquee Parco Ciani)8:00–8:45 **MEET THE PROFESSOR SESSIONS** 
(five parallel sessions, repetition of some of Wednesday session)

- XIII. Waldenström Macroglobulinemia: just another indolent lymphoma? (Room A)
S.P. Treon, Boston, MA (USA)
- XIV. The rationale for combining targeted and biological anti-lymphoma drugs (Room B)
A. Younes, New York, NY (USA)
- XV. Malignant lymphoma as a consequence of clonal evolution (Cinema Corso)
M. Seto, Nagoya (Japan)
- VIII. New markers in T-cell lymphoma: more entities or more confusion? (USI Auditorium, University Campus Lugano)
P. Gaulard, Créteil (France)
- XVI. CNS prophylaxis in aggressive lymphomas: for whom and how (USI Aula Magna, University Campus Lugano)
U. Vitolo, Turin (Italy)

9:00–10:30 **SESSION 2—CLL BIOLOGY** (Room A and Marquee Parco Ciani)
Chairs: J. Gribben, London (UK), and M. Hallek, Cologne (Germany)

- 9:00 049 Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
D. Rossi, Novara (Italy)
- 9:15 050 Microna MIR-150 contributes to the disease aggressiveness and regulation of B-cell receptor signaling (BCR) in chronic lymphocytic leukemia
M. Mraz, San Diego, CA (USA)
- 9:30 051 Identification of circulating chronic lymphocytic leukemia intraclonal subgroups with varying B cell receptor function
F. Forconi, Southampton (UK)
- 9:45 052 Impact of initial clinicobiological features, including genetic mutations, in the development of accelerated chronic lymphocytic leukemia or transformation to diffuse large B cell lymphoma in CLL
E. Gine, Barcelona (Spain)
- 10:00 053 Clinical impact of mutations in genes of the toll-like receptor (TLR/MyD88) pathway in chronic lymphocytic leukemia (CLL)
A. Martinez-Trillos, Barcelona (Spain)
- 10:15 054 Over-expression of TP53 mRNA in chronic lymphocytic leukemia is associated with low 13Q14 copy number; reduced MIR-15A/16-1 levels and adverse outcome
K. Lin, Liverpool (UK)

9:00–10:30
(Five parallel sessions)**'CASE DISCUSSION' SESSIONS****INDOLENT LYMPHOMAS** (Room B)

Chair: M. Ghielmini, Bellinzona (Switzerland)

Discussants: F. Morschhauser, Lille (France) and T.E. Witzig, Rochester, MN (USA)

PAEDIATRIC AND ADOLESCENT LYMPHOMAS (Room C)

Chair: A. Reiter, Giessen (Germany)

Discussants: C. Patte, Villejuif (France) and S. Weitzman, Toronto, Ontario (Canada)

T-CELL LYMPHOMAS (Cinema Corso)

Chair: J. Seymour, Melbourne (Australia)

Discussants: S. M. Ansell, Rochester, MN (USA) and R. Delarue, Paris (France)

MULTIPLE MYELOMA (USI Auditorium, University Campus Lugano)

Chair: S.P. Treon, Boston, MA (USA)

Discussants: S.K. Kumar, Rochester, MN (USA) and P. Moreau, Nantes (France)

(Continues)

(Continued)

Thursday, June 20, 2013

| | | |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | HODGKIN LYMPHOMAS (USI Aula Magna, University Campus Lugano) Chair: M. Federico, Modena (Italy) Discussants: M.P.E. André, Leuven (Belgium) and I.N. Micallef, Rochester, MN (USA) |
| 10:30–10:50 | | COFFEE BREAK (Marquee Parco Ciani) |
| 10:50–12:05 | | SESSION 3—ADVANCES IN THE CLINICAL MANAGEMENT OF CLL (Rooms A, B, and Marquee) Chairs: E. Montserrat, Barcelona (Spain), and S. O'Brien, Houston, TX (USA) |
| 10:50 | 055 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia (CLL) J. Bahlo, Cologne (Germany) |
| 11:05 | 056 | Obinutuzumab (GA101) + chlorambucil (CLB) or rituximab (R) + CLB versus CLB alone in patients with chronic lymphocytic leukemia (CLL) and pre-existing medical conditions (comorbidities): Final stage I results of the CLL I I (BO21004) Phase 3 trial M. Hallek, Cologne (Germany) |
| 11:20 | 057 | Updated results of a Phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) J. Seymour, Melbourne (Australia) |
| 11:35 | 058 | Correlation between TP53 mutation or deletion and efficacy with single-agent lenalidomide in patients with relapsed or refractory (REL/REF) chronic lymphocytic leukemia (CLL) (CC-5013-CLL-009 study) A. Buhler, Cologne (Germany) |
| 11:50 | 059 | Evidence that allogeneic transplantation (alloHCT) can improve the natural course of poor-risk chronic lymphocytic leukemia (CLL): final results from a retrospective donor vs no donor comparison P. Dreger, Heidelberg (Germany) |
| 12:05–13:00 | | LUNCH TIME AND PRESENTATION OF BEST 'PRE-CLINICAL' POSTERS (Marquee Parco Ciani) by R. Dalla-Favera, New York, NY (USA) Posters #168, 170, 177, 180, 228 and 240 |
| 13:00–13:50 | | HENRY RAPPAPORT MEMORIAL LECTURE (Rooms A, B, and Marquee Parco Ciani)  Chair: P. Gaulard, Créteil (France) |
| | 002 | Illuminating the incipient events in lymphoid neoplasms E.S. Jaffe, Bethesda, MD (USA) |
| 13:50–15:20 | | SESSION 4—FOLLICULAR LYMPHOMA (Rooms A, B, and Marquee) Chairs: A. Lopez Guillermo, Barcelona (Spain) and M. Seto, Nagoya (Japan) |
| 13:50 | 060 | The structure of stepwise clonal evolution events shaping follicular lymphoma coding genomes A.A. Alizadeh, Stanford, CA (USA) |
| 14:05 | 061 | Genomic analysis reveals the evolution patterns and key pathways fundamental for the initiation and progression of follicular lymphoma J. Okosun, London (UK) |
| 14:20 | 062 | Managing Stage I-II follicular lymphoma with upfront definitive radiation therapy: the forty-year experience of the Princess Margaret Cancer Centre A. Charpentier, Toronto, Ontario (Canada) |
| 14:35 | 063 | CALGB 50803(Alliance): a Phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma P. Martin, New York, NY (USA) |
| 14:50 | 064 | Salvage chemotherapy (SC) and autologous stem cell transplantation (ASCT) for transformed indolent lymphoma (TR): a subgroup analysis of NCIC CTG LY12 J. Kuruwilla, Toronto, Ontario (Canada) |
| 15:05 | 064bis | Interim results from a phase 2 study of PI3K δ inhibitor idelalisib in patients with relapsed indolent non-hodgkin lymphoma (INHL) refractory to both rituximab and an alkylating agent G. Salles, Pierre Benite (France) |

(Continues)

(Continued)

Thursday, June 20, 2013

- 15:20–15:35 **COFFEE BREAK** (Marquee Parco Ciani)
- 15:35–17:05 **SESSION 5—TARGETING THE BCR-NFκB PATHWAYS** (Room A and Marquee)
Chairs: G. Salles, Pierre Bénite (France) and L.M. Staudt, Bethesda, MD (USA)
- 15:35 Introduction: L.M. Staudt, Bethesda, MD (USA)
- 15:50 065 The IκB family member NFKBIZ regulates NF-κB signaling and is critical for survival of ABC DLBCL
G. Lenz, Berlin (Germany)
- 16:05 066 Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,-γ, in patients with relapsed/refractory B-cell lymphoma
B. Kahl, Madison, WI (USA)
- 16:20 067 A prospective, multicenter, Phase II study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenström's macroglobulinemia
S.P. Treon, Boston, MA (USA)
- 16:35 068 Combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine are tolerable and highly active in patients with previously treated, indolent non-Hodgkin lymphoma (INHL): updated results from a Phase I study
J.P. Leonard, New York, NY (USA)
- 16:50 069 Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)
A. Younes, New York, NY (USA)
- 15:35–17:05 **SESSION 6—PATHOLOGY AND CLINICOPATHOLOGIC CORRELATIONS** (Room B)
Chairs: S.A. Pileri, Bologna (Italy) and S. Dimhofer, Basel (Switzerland)
- 15:35 070 Classification of non-Hodgkin lymphoma in six geographic regions around the world: review of 4539 cases from the international non-Hodgkin lymphoma classification project
A. Perry, Winnipeg, Manitoba (Canada)
- 15:50 071 Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies
A. Traverse-Glehen, Pierre Bénite (France)
- 16:05 072 In situ follicular lymphoma: a genetic viewpoint
E. Mamessier, Marseille (France)
- 16:20 073 T(14;18) translocation: a predictive blood biomarker for follicular lymphoma
S. Roulland, Marseille (France)
- 16:35 074 The host genetic background modulates treatment activity and toxicity in follicular lymphoma: FIL-FOLL05 trial
G.A. Palumbo, Catania (Italy)
- 16:50 075 Study on the biology and treatment of mediastinal grey zone lymphoma
K. Dunleavy, Bethesda, MD (USA)
- 15:35–18:05 **SESSION 7—PAEDIATRIC LYMPHOMA** (Room C)
Chair: A. Reiter, Giessen (Germany)
- 15:35 076 Alk tyrosine kinase inhibitors for Alk+ anaplastic large cell lymphoma (ALCL): preliminary clinical experiences and perspectives
T.G. Gross, Columbus, OH (USA)
- 16:05 077 Mechanisms of resistance to Alk tyrosine kinase inhibitors and strategies to overcome them
R. Chiarle, Turin (Italy)
- 16:35 078 Detection of anti-NPM-Alk CD8⁺ T cells in children with NPM-Alk-positive anaplastic large cell lymphoma (ALCL)
V.K. Singh, Giessen (Germany)
- 16:50 079 CNS disease in pediatric patients with B-cell non-Hodgkin lymphoma and Burkitt leukemia—therapy and outcome in the B-NHL BFM 04 study
J. Lisfeld, Giessen (Germany)

(Continues)

(Continued)

Thursday, June 20, 2013

| | | |
|-----------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:05 | 080 | Different pattern of chromosomal alterations according to the morphology and the age in childhood mature B-cell lymphomas: report of the French LMB2001/03 study H.A. Poirel, Brussels (Belgium) |
| 17:20 | 081 | Paediatric Burkitt lymphoma of the NHL-BFM group analyzed within the ICGC-MMML-Seq; whole genome sequencing data from 12 cases M. Rohde, Giessen (Germany) |
| 17:35 | 082 | Ten-year follow up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation L.G. Roth, New York, NY (USA) |
| 17:50 | 083 | Clinical presentation and outcome of advanced stage classical Hodgkin's lymphoma in children: a retrospective study A.S. Dongre, Mumbai (India) |
| 17:15–18:15 (Five parallel sessions) | | 'FOCUS ON...' SESSIONS OLD AND NEW RANDOMIZED TRIALS (Room A) Chair: B. Coiffier, Pierre Bénite (France) |
| 17:15 | 084 | The bright study of first-line bendamustine-rituximab (BR) or R-CHOP/R-CVP in advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL) I. Flinn, Nashville, TN (USA) |
| 17:25 | 085 | Gemcitabine, dexamethasone, cisplatin (GDP) compared to dexamethasone, cytarabine, cisplatin (DHAP) salvage chemotherapy prior to autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: final results of the Phase III NCIC CTG study LY12 M. Crump, Toronto, Ontario (Canada) |
| 17:35 | 086 | Alternating courses of 3X CHOP and 3X DHAP plus rituximab followed by a high dose Ara-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL NET) O.R. Hermine, Paris (France) |
| 17:45 | 087 | Preliminary results of prospective randomized multicenter study "BEACOPP-14 vs BEACOPP-escalated in patients with Hodgkins lymphoma from poor-prognosis group" I.A. Kriachok, Kiev (Ukraine) |
| 17:55 | 088 | First-line R-CVP versus R-CHOP induction therapy and maintenance rituximab for indolent lymphoma. a multicenter Phase III randomized study PLRG-4 by the Polish lymphoma research group J. Walewski, Warsaw (Poland) |
| 18:05 | 089 | Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB 50403 L.D. Kaplan, San Francisco, CA (USA) |
| 17:15–18:15 | | LYMPHOMA GENOMICS (Room B) Chair: M.A. Piris, Santander (Spain) |
| 17:15 | 090 | High resolution ChIP-sequencing reveals novel targets and prognostic role for SOX11 in mantle cell lymphoma S. Parekh, New York, NY (USA) |
| 17:25 | 091 | Deregulation of Ets1 and Fli1 expression is recurrent in DLBCL leading to tumor proliferation and B-cell maturation blockage M. Testoni, Bellinzona (Switzerland) |
| 17:35 | 092 | Conditional activation of the Hodgkin LYMPHOMA-associated HLH factors ID2 and ABFI disrupts B cell differentiation in vivo M. Janz, Berlin (Germany) |
| 17:45 | 093 | Recurring activation mutations and somatic deletions revealed through whole genome sequencing in Waldenström's macroglobulinemia Z. Hunter, Boston, MA (USA) |

(Continues)

(Continued)

Thursday, June 20, 2013

- | | | |
|-------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:55 | 094 | PLCGI mutations in cutaneous T-cell lymphomas M. Sanchez-Beato, Madrid (Spain) |
| 18:05 | 095 | Next-generation sequencing suggests therapeutic targets in peripheral T-cell lymphoma J.H. Schatz, Tucson, AZ (USA) |
| 17:15–18:15 | | EXTRANODAL LESIONS (Cinema Corso) Chair: C. Thieblemont, Paris (France) |
| 17:15 | 096 | Primary cutaneous diffuse large B-cell lymphoma, LEG-type (PCDLBCL-LT) harbours the genetic profile of nodal activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) A. Pham-Ledard, Pessac (France) |
| 17:25 | 097 | The role of rituximab and PET in the treatment of primary mediastinal large B-cell lymphoma P. Zinzani, Bologna (Italy) |
| 17:35 | 098 | The impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement G. Held, Homburg (Germany) |
| 17:45 | 099 | A prospective Phase II trial of an L-asparaginase containing regimen in extra nodal NK/T-cell lymphoma A. Jaccard, Limoges (France) |
| 17:55 | 100 | Bendamustine plus rituximab in first line systemic treatment for extranodal malt lymphoma: final results of Phase II trial of the Spanish lymphoma study group (GELTAMO) A. Salar, Barcelona (Spain) |
| 18:05 | 101 | Clinical outcomes and patterns of relapse in 320 patients with early and advanced-stage marginal zone lymphoma: the role of radiotherapy S. Teckie, New York, NY (USA) |
| 17:15–18:15 | | TREATING THE ELDERLY PATIENT (USI Auditorium, University Campus Lugano) Chair: T.E. Witzig, Rochester, MN (USA) |
| 17:15 | 102 | Disease characteristics, patterns of care, and outcomes of follicular lymphoma (FL) in the oldest old: report from the US national lymphocare study (NLCS) C. Nabhan, Park Ridge, IL (USA) |
| 17:25 | 103 | Inferior outcome of elderly DLBCL patients with 25-OH vitamin D deficiency treated with CHOP plus rituximab (R): results of the ricover-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL) J.T. Bittenbring, Homburg (Germany) |
| 17:35 | 104 | Brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly de novo advanced stage follicular lymphoma (FL) patients: a study by Fondazione Italiana Linfomi (FIL) C. Boccomini, Turin (Italy) |
| 17:45 | 105 | Major responses in over 90% of older patients treated with F(C)R based chemotherapy—the Australasian leukemia and lymphoma group (ALLG) CLL5/OFOCIR study S.P. Mulligan, Sydney (Australia) |
| 17:55 | 106 | Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense IV rituximab (R) in previously untreated patients with chronic lymphocytic leukemia (CLL) aged ≥ 65 years: results of a multicenter trial (LLC 2007 SA) on behalf of the French Goelams/Fcgll/WMM intergroup E. Van Den Neste, Brussels (Belgium) |
| 18:05 | 107 | First line therapy of elderly patients with chronic lymphocytic leukemia (CLL)—long term follow-up (FU) results of a randomized Phase III study of the German CLL study group (CLL5 study of the GCLLSG) B. Eichhorst, Cologne (Germany) |
| 17:15–18.15 | | MANTLE CELL LYMPHOMA (USI Aula Magna, University Campus Lugano) Chair: J.P. Leonard, New York, NY (USA) |
| 17:15 | 108 | Deep B and T cell repertoire sequencing to evaluate minimal residual disease and T cell responses in a therapeutic vaccine trial for mantle cell lymphoma R. Levy, Stanford, CA (USA) |

(Continues)

(Continued)

Thursday, June 20, 2013

| | | |
|-------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17:25 | 109 | Reprogramming MCL for cytotoxic killing by targeting CDK4/CDK6 S. Chen-Kiang, New York, NY (USA) |
| 17:35 | 110 | A high PIK3CA/PIK3CD mRNA ratio in mantle cell lymphoma can predict resistance to PI3K δ inhibition and is more common with multiple relapse S. Iyengar, London (UK) |
| 17:45 | 111 | Radioimmunotherapy as consolidation in MCL (mantle cell lymphoma)—8 years follow-up of a prospective Phase 2 polish lymphoma research group study W. Jurczak, Krakow (Poland) |
| 17:55 | 112 | Outcome after RIC allo-stem cell transplantation for patients with mantle cell lymphoma who relapsed after autologous stem cell transplantation, a retrospective study of the SFGM-TC group S. Le Gouill, Nantes (France) |
| 18:05 | 113 | Targeting the IRF4/MYC axis in bortezomib-resistant mantle cell lymphoma with lenalidomide and BET bromodomain inhibition G. Roue, Barcelona (Spain) |

Friday, June 21, 20138:30–18:30 **POSTER SESSION** (Marquee Parco Ciani)8:00–8:45 **MEET THE PROFESSOR SESSIONS** 

(Five parallel sessions, repetition of some of Wednesday session)

- XII. Hodgkin's lymphoma in the elderly (Room A)
A.M. Evens, Worcester, MA (USA)
- IX. CLL: new genetic markers as prognostic factors (Room B)
D. Rossi, Novara (Italy)
- X. Extranodal lymphomas in rare localisations (bone, breast and others) (USI Aula Magna, University Campus Lugano)
J.F. Seymour, Melbourne (Australia)
- XIV. The rationale for combining targeted and biological anti-lymphoma drugs (USI Auditorium, Lugano University)
A. Younes, New York, NY (USA)
- XVI. CNS prophylaxis in aggressive lymphomas: for whom and how (Cinema Corso)
U. Vitolo, Turin (Italy)

9:00–10:30 **SESSION 8—TARGETING THE LYMPHOMA EPIGENOME** (Room A and Marquee)
Chair: L. Pasqualucci, New York, NY (USA) and A. Younes, New York, NY (USA)

9:00 Introduction: L. Pasqualucci, New York, NY (USA)

9:15 I14 The BRD-inhibitor OTX015 is active in pre-clinical B-cell lymphoma models and affects relevant pathogenetic pathways
F. Bertoni, Bellinzona (Switzerland)9:30 I15 Preclinical characterization of E7438, a potent, selective inhibitor of protein methyltransferase EZH2 with robust antitumor activity against EZH2 mutated non-Hodgkin lymphoma xenografts in mice
K. Kuntz, Cambridge, MA (USA)9:45 I16 Sirtuin and pan-Class I/II deacetylase (DACI) inhibition is synergistic in preclinical models and clinical studies of lymphomas
O.A. O'Connor, New York, NY (USA)10:00 I17 The pan-histone deacetylase inhibitor (HDACI) abexinostat (PCI-24781): significant clinical activity in relapsed/refractory (R/R) follicular lymphoma (FL) in a multicenter Phase II study
A.M. Evens, Worcester, MA (USA)10:15 I18 A Phase IB/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the RO-CHOP study
J. Dupuis, Créteil (France)

9:00–10:30

(Four parallel sessions)

'CASE DISCUSSION' SESSIONS**AGGRESSIVE LYMPHOMAS** (Room B)

Chair: J.W. Friedberg, Rochester, NY (USA)

Discussants: G.S. Nowakowski, Rochester, MN (USA) and G. Salles, Pierre Bénite (France)

CLL (Cinema Corso)

Chair: G. Gaidano, Novara (Italy)

Discussants: T.D. Shanafelt, Rochester, MN (USA) and L. Ysebaert, Toulouse (France)

EXTRANODAL LYMPHOMAS (USI Auditorium, University Campus Lugano)

Chair: M. Gospodarowicz, Toronto, Ontario (Canada)

Discussants: P.B. Johnston, Rochester, MN (USA) and T. Lamy de La Chapelle, Rennes (France)

MCL (USI Aula Magna, University Campus Lugano)

Chair: M. Dreyling, Munich (Germany)


Discussants: T.M. Habermann, Rochester, MN (USA) and S. Le Gouill, Nantes (France)

10:30–10:50 **COFFEE BREAK** (Marquee Parco Ciani)

(Continues)

(Continued)

Friday, June 21, 2013

- 11:00–18:00 **FIRST NURSING SESSION*** (USI Auditorium, University Campus Lugano)
Chair: M. Bianchi, Bellinzona (Switzerland)
*Organized by Oncology Institute of Southern Switzerland (IOSI) and European Institute of Oncology (IEO)
(Official language: Italian—no translation provided)
- 10:50–12:05 **SESSION 9—DLBCL TREATMENT STRATEGIES** (Rooms A, B, and Marquee)
Chairs: L. Specht, Copenhagen (Denmark) and K. Tobinai, Tokyo (Japan)
- 10:50 119 Rituximab maintenance treatment versus observation in patients with aggressive B-cell lymphoma: results of the AGMT NHL13 trial
U. Jaeger, Wien (Austria)
- 11:05 120 Chemoimmunotherapy with R-CHOP or high dose sequential therapy (R-HDS) with autologous stem cell transplantation (ASCT) for high risk DLBCL patients: preliminary results of the randomized R-HDS0305 trial by Gruppo Italiano Terapie Innovative nei Linfomi (GITIL)
S. Cortelazzo, Bolzano (Italy)
- 11:20 121 Role of radiation in patients with diffuse large B cell lymphoma (DLBCL) in the rituximab era: a comprehensive analysis from the national comprehensive cancer network (NCCN) lymphoma outcomes project
B. Dabaja, Houston, TX (USA)
- 11:35 122 The role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. results from 2 prospective trials of the DSHNHL
C. Zwick, Homburg (Germany)
- 11:50 123 Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP
L.H. Sehn, Vancouver, BC (Canada)
- 12:05–13:00 **LUNCH TIME AND PRESENTATION OF BEST 'CLINICAL' POSTERS** (Marquee Parco Ciani)
by M. Dreyling, Munich (Germany)
Posters # 188, 194, 196, 214, 217 and 226
- 13:00–14:00 **JOHN ULTMANN MEMORIAL LECTURE*** (Rooms A, B, and Marquee Parco Ciani) 
* ASCO-ICML joint symposium
Chair: G.B. Canellos, Boston, MA (USA)
- 003 Hodgkin lymphoma—the great teacher
J.M. Connors, Vancouver, BC (Canada)
- 14:00–15:15 **SESSION 10—FRONT-LINE TREATMENT OF HODGKIN'S LYMPHOMA** (Rooms A, B, and Marquee)
Chairs: A. Engert, Cologne (Germany) and R. Pettengell, London (UK)
- 14:00 124 A Phase II trial of response-adapted therapy of Stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging: U.S. intergroup S0816
O.W. Press, Seattle WA (USA)
- 14:15 125 PET-CT adapted therapy after 3 cycles of ABVD to all stages of Hodgkin lymphoma: a report from the Gatla Group
A. Pavlovsky, Buenos Aires (Argentina)
- 14:30 126 Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study
P.W.M. Johnson, Southampton (UK)
- 14:45 127 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles \geq 4 baseline) in Stage III-IV low risk Hodgkin lymphoma (IPS 0–2): final results of lisa H34 trial
N. Mounier, Nice (France)
- 15:00 128 **REPORT OF 11-ICML CLOSED WORKSHOP** on “Lymphoma pretreatment assessment and response criteria in the new millennium: beyond Ann Arbor”
B.D. Cheson, Washington D.C. (USA)

(Continues)

(Continued)

Friday, June 21, 2013

| | | |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:15 | BREAK | |
| 15:30–16:15 | CONTROVERSY II (Room A, B, and Marquee) Does radiotherapy remain the standard component of treatment in early stage Hodgkin lymphoma? Chair: B.D. Cheson, Washington D.C. (USA) 129 Yes—T. Illidge, Manchester (UK) vs 130 No—M. Gospodarowicz, Toronto, Ontario (Canada) | |
| 16:15–17:35 | PRESENTATION OF ONGOING TRIALS (Rooms A, B, and Marquee) Chairs: R.I. Fisher, Philadelphia, PA (USA) and M. Federico, Modena (Italy) | |
| 16:15 | 131 | Phase 3 trial comparing GA101 (obinutuzumab) + CHOP (G-CHOP) vs rituximab + CHOP (R-CHOP) in previously untreated DLBCL M. Mobasher, South San Francisco, CA (USA) |
| 16:25 | 132 | Gene expression profiling (GEP) to identify subtypes of diffuse large B-cell lymphoma (DLBL) for randomisation to R-CHOP +/- bortezomib. A trial in progress in the UK NCRI and SAKK lymphoma groups: REMoDL-B, ISRCTN51837425 A. Davies, Southampton (UK) |
| 16:35 | 133 | A randomised, multicentre, two-arm Phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL). The IELSG37 study M. Martelli, Rome (Italy) |
| 16:45 | 134 | CLLM1: a recruiting Phase 3 study of the efficacy and safety of lenalidomide as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy A.M. Fink, Cologne (Germany) |
| 16:55 | 135 | A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (INHL) M.S. Czuczman, Buffalo, NY (USA) |
| 17:05 | 136 | The "relevance" trial: a lysa sponsored Phase 3 randomized study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab plus any chemotherapy in subjects with previously untreated advanced follicular lymphoma F. Morschhauser, Lille (France) |
| 17:15 | 137 | A Phase 3 study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL) M. Dreyling, Munich (Germany) |
| 17:25 | 138 | Echelon-2: Phase 3 trial of brentuximab vedotin and CHP versus chop in the frontline treatment of patients (PTS) with CD30+ mature T-cell lymphomas (MTCL) O.A. O'Connor, New York, NY (USA) |
| 17:35–18:35 | FAREWELL APERO (Marque Parco Ciani) | |

Saturday, June 22, 2013

8:00–10:30

SPECIAL SESSION—CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING* (USI room 159 - University Campus Lugano)

Chairs: L. Specht, Copenhagen (Denmark) and J. Yahalom, New York, NY (USA)

*Organized by ILROG – International Lymphoma Radiation Oncology Group and endorsed by ESTRO – European Society for Radiotherapy and Oncology

For lymphoma radiation oncologists: maximum number 30. Registration closed.

8:30–9:30

(Two parallel sessions)

'FOCUS ON...' SESSIONS**RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA** (Room A)

Chairs: T.A. Lister, London (UK)

8:30

139 Pilot Phase 2 study of Idelalisib, a selective inhibitor of PI3K δ , in patients with heavily pretreated Hodgkin lymphoma (HL)

A. Younes, New York, NY (USA)

8:40

140 Two-year followup of patients with relapsed/refractory Hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantation

R. Chen, Duarte, CA (USA)

8:50

141 PET-adapted sequential therapy with brentuximab vedotin and augmented-ice induces FDG-PET normalization in 92% of patients with relapsed and refractory Hodgkin lymphoma

A.J. Moskowitz, New York, NY (USA)

9:00

142 Prognostic factors in patients (PTS) with relapsed/refractory (R/R) Hodgkin's lymphoma (HL) treated with IGEV and autologous stem cell transplantation (ASCT): a nationwide retrospective survey from Fondazione Italiana Linfomi (FIL)

M. Balzarotti, Rozzano (Italy)

9:10

143 Long-term outcome of adults with first relapsed or refractory Hodgkin lymphoma treated in the prospective LYSA/SFGM-TC H96 trial

D. Sibon, Paris (France)

9:20

144 Serum TARC level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in Hodgkin's lymphoma patients

L. Farina, Milan (Italy)

8:30–9:30

PHASE I-II TRIALS (Room B)

Chair: A.H. Goy, Hackensack, NJ (USA)

8:30

145 Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase- δ , γ , in patients with relapsed/refractory CLL/SLL

I.W. Flinn, Nashville, TN (USA)

8:40

146 Updated results of a Phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)

M. Davids, Boston, MA (USA)

8:50

147 Cell cycle inhibition with PD0332991 sensitizes MCL to killing by bortezomib: a Phase I trial

P. Martin, New York, NY (USA)

9:00

148 Phase I study of R-CVP plus inotuzumab ozogamicin (INO) in CD22+ B-cell non-Hodgkin lymphoma (B-NHL)

M. Ogura, Nagoya (Japan)

9:10

149 Temsirolimus added to bendamustin and rituximab (BERT): Phase I results of a Phase I/II-trial in patients with relapsed follicular lymphoma (FL) and mantle cell lymphoma (MCL)

G. Hess, Mainz (Germany)


9:20


150 Prospective Phase II clinical trial of carfilzomib, rituximab and dexamethasone (CARD) in Waldenström's macroglobulinemia (WM)

(Continues)

(Continued)

Saturday, June 22, 2013

- S.P. Treon, Boston, MA (USA)
- 9:45–11:00
(Two parallel sessions)
- SESSION 11—T-CELL NEOPLASIA** (Room A)
Chairs: C. Gisselbrecht, Paris (France) and J.M. Vose, Omaha, NE (USA)
- 9:45 151 CD30 in PTCLS: correlation between RNA and protein levels in a large European series from the lisa
C. Bossard, Nantes (France)
- 10:00 152 Safety and efficacy of brentuximab vedotin for treatment of relapsed or refractory mature T-/NK-cell
lymphomas
Y. Oki, Houston, TX (USA)
- 10:15 153 Belinostat in relapsed or refractory peripheral T cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-
cell lymphoma (AITL): results from the pivotal belief trial
S. Horwitz, New York, NY (USA)
- 10:30 154 Combination of mogamulizumab (KW-0761) with VCAP-AMP-VECP (MLSG15) is well tolerated and
effective as an initial therapy for aggressive adult T-cell leukemia-lymphoma (ATL)
S. Takemoto, Kumamoto (Japan)
- 10:45 155 Intensified chemo-immunotherapy for patients affected by nodal peripheral T-cell lymphomas (PTCLS) at
diagnosis: final results of a Phase II multicenter prospective trial
P. Corradini, Milan (Italy)
- 9:45–11:15
- SESSION 12—LYMPHOMA MICROENVIRONMENT** (Room B)
Chairs: E. Campo, Barcelona (Spain) and J.P. Leonard, New York, NY (USA)
- 9:45 Introduction: E. Campo, Barcelona (Spain)
- 10:00 156 T-cell and monocyte profiling shows marked differences in fresh tissue gene expression between positively
selected tumor infiltrating and peripheral blood cells in follicular non-Hodgkin's lymphoma (FL): possible
role of heat shock protein 70 (HSP70) and B-cell receptor activating genes in disease progression and
transformation
S.M. Rassam, Kent (UK)
- 10:15 157 A diffuse large B-cell lymphoma associated-macrophage transcriptome analysis reveals a unique M1-M2
polarization profile that challenges current concepts on the lymphoma microenvironment
R. Coutinho, London (UK)
- 10:30 158 CSF-1R inhibition depletes tumor-associated macrophages and is a rational novel clinical strategy in
aggressive B-lymphomas
S. Hallam, London (UK)
- 10:45 159 Phase II safety and efficacy study of pidilizumab in combination with rituximab in patients with relapsed
follicular lymphoma
J.R. Westin, Houston, TX (USA)
- 11:00 160 CD163+ identifies a highly immunosuppressive subset of monocytic-myeloid derived suppressor cells
(MOMDSC) in poor-risk diffuse large B-cell lymphoma (DLBCL): an ALLG laboratory sub-study of NHL21
C. Keane, Brisbane (Australia)
- 11:15–11:45
- 12-ICML HIGHLIGHTS** (Rooms A and B) 
'Take home messages'
J.O. Armitage, Omaha, NE (USA)
- 13:15–18:00
- WORKSHOP: "CANINE LYMPHOMAS: STATE OF THE ART AND COMPARATIVE ASPECTS WITH HUMAN DISEASE"**
* (OPEN TO ALL 12-ICML ATTENDEES—Room B)
Chairs: S. Comazzi, F. Guscetti and L. Marconato, Milan (Italy)
*Organized by the European Canine Lymphoma Group

 This icon denotes presentations that will be available online, only for ICML attendees, between July 15 and September 15, 2013.

EDUCATIONAL BOOK

The 12-ICML Educational Book is kindly supported by an unrestricted educational grant from sigma-tau Research Switzerland SA.

LIST OF EDUCATIONAL SYMPOSIA ARTICLES:

- I. Pathological and clinical diversity in DLBCL—M.A. Piris, Santander (Spain)
- II. Therapy of DLBCL based on genomics—L.M. Staudt, Bethesda, MD (USA)
- III. Applying molecular phenotyping in practice—P.W.M. Johnson, Southampton (UK)
- IV. Initial therapy of myeloma—S.V. Rajkumar, Rochester, MN (USA)
- V. Molecular classification and risk stratification of myeloma—P.L. Bergsagel, Scottsdale, AZ (USA)
- VI. Autologous stem cell transplantation and maintenance therapy—P. Moreau, Nantes (France)

LIST OF MEET THE PROFESSOR ARTICLES:

- VII. Management of nodular lymphocyte predominant Hodgkin's Lymphoma—A. Engert, Cologne (Germany)
- VIII. New markers in T-cell lymphoma: more entities or more confusion?—P. Gaulard, Créteil (France)
- IX. CLL: new genetic markers as prognostic factors—D. Rossi, Novara (Italy)
- X. Extranodal lymphomas in rare localisations (bone, breast, and others)—J.F. Seymour, Melbourne (Australia)
- XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?—W. Woessmann, Giessen (Germany)
- XII. Hodgkin's lymphoma in the elderly—A.M. Evens, Worcester MA (USA)
- XIII. Waldenström Macroglobulinemia: just another indolent lymphoma?—S.P. Treon, Boston MA (USA)
- XIV. The rationale for combining targeted and biological anti-lymphoma drugs—A. Younes, New York, NY (USA)
- XV. Malignant lymphoma as a consequence of clonal evolution—M. Seto, Nagoya (Japan)
- XVI. CNS prophylaxis in aggressive lymphomas: for whom and how—U. Vitolo, Turin (Italy)
- XVII. Radiotherapy in early-stage Hodgkin Lymphoma—T. Illidge, Manchester (UK)

Article related to abstract 129

Note: The articles published in the 12-ICML Educational Book represent the presentations made at the “Educational Symposia” and “Meet the Professor” sessions during the 12th International Conference on Malignant Lymphoma (12-ICML) held in Lugano, Switzerland on June 19–22, 2013.

All manuscripts submitted have been subjected to peer review, and authors have been requested to disclose any relationships with the companies whose products or services are discussed in their manuscripts.

Prof Michele Ghilmini, as guest editor, has reported no financial relationships with companies whose products are mentioned in this supplement.

12-ICML REVIEWERS' LIST

The 12-ICML Organizing Committee wishes to thank the following colleagues for their professional help:

J.O. Armitage, Omaha, NE (USA)
 T. Batchelor, Boston, MA (USA)
 F. Bertoni, Bellinzona (Switzerland)
 E. Campo, Barcelona (Spain)
 F. Cavalli, Bellinzona (Switzerland)
 B.D. Cheson, Washington, D.C. (USA)
 B. Coiffier, Pierre Bénite (France)
 J.M. Connors, Vancouver, BC (Canada)
 F.E. Cotter, London (UK)
 R. Dalla-Favera, New York, NY (USA)
 A. Davies, Southampton (UK)
 S. De Sanjose Llongueras, L'Hospitalet-Barcelona (Spain)
 R. Dolcetti, Aviano (Italy)
 P. Dreger, Heidelberg (Germany)
 M. Dreyling, Munich (Germany)
 R. Dummer, Zürich (Switzerland)
 A. Engert, Cologne (Germany)
 M.R. Federico, Modena (Italy)
 A.J. Ferreri, Milan (Italy)
 M.F. Fey, Bern (Switzerland)
 J.W. Friedberg, Rochester, NY (USA)
 G. Gaidano, Novara (Italy)
 R.D. Gascoyne, Vancouver, BC (Canada)
 P. Gaulard, Créteil (France)
 M. Ghilmini, Bellinzona (Switzerland)
 C. Gisselbrecht, Paris (France)
 M.K. Gospodarowicz, Toronto (Canada)
 T.G. Gross, Columbus, OH (USA)
 A. Hagenbeek, Amsterdam (Netherlands)
 M. Hallek, Cologne (Germany)
 N.L. Harris, Boston, MA (USA)
 G. Illerhaus, Stuttgart (Germany)
 T. Illidge, Manchester (UK)
 E.S. Jaffe, Bethesda, MD (USA)
 P.W. Johnson, Southampton (UK)
 B. S. Kahl, Madison, WI (USA)
 I. Khouri, Houston, TX (USA)
 M. Ladetto, Turin (Italy)
 G. Lenz, Berlin (Germany)
 J.P. Leonard, New York, NY (USA)
 E. Lerch, Bellinzona (Switzerland)
 R. Levy, Stanford, CA (USA)
 A.T. Lister, London (UK)
 A. López Guillermo, Barcelona (Spain)
 M. Meignan, Créteil (France)
 A. Moccia, Bellinzona (Switzerland)
 S. Montoto, London (UK)
 E. Montserrat Costa, Barcelona (Spain)
 P. Moreau, Nantes (France)
 G. Nowakowski, Rochester, MN (USA)
 C. Patte, Villejuif (France)
 M. Pfreundschuh, Homburg (Germany)
 S.A. Pileri, Bologna (Italy)
 M.A. Piris, Santander (Spain)
 M. Ponzoni, Milan (Italy)
 B. Pro, Philadelphia, PA (USA)
 M. Raderer, Vienna (Austria)
 J. Radford, Manchester (UK)
 S. V. Rajkumar, Rochester, MN (USA)
 A. Reiter, Giessen (Germany)
 A. Rosenwald, Würzburg (Germany)
 D. Rossi, Novara (Italy)
 G. Salles, Pierre Bénite (France)
 F. Sallusto, Bellinzona (Switzerland)
 M. Seto, Nagoya (Japan)
 J.F. Seymour, East Melbourne (Australia)
 M.A. Shipp, Boston, MA (USA)
 L. Specht, Copenhagen (Denmark)
 M. Spina, Aviano (Italy)
 A. Stathis, Bellinzona (Switzerland)
 L.M. Staudt, Bethesda, MD (USA)
 S. Stroobants, Antwerpen (Belgium)
 C. Thieblemont, Paris (France)
 K. Tobinai, Tokyo (Japan)
 U. Vitolo, Turin (Italy)
 J.M. Vose, Omaha, NE (USA)
 D.D. Weisenburger, Duarte, CA (USA)
 S. Weitzman, Toronto, Ontario (Canada)
 W. Wilson, Bethesda, MD (USA)
 A. Younes, New York, NY (USA)
 P.L. Zinzani, Bologna (Italy)
 E. Zucca, Bellinzona (Switzerland)